Introducing Panalgo, formerly BHE.

Read Our Story

Our Team

Our diverse team includes experts in research, technology and business.

Company Leadership

Joseph Mezin

Joseph Menzin, PhD

Founder & Chief Executive Officer
Joseph Menzin, Ph.D. is the CEO of Panalgo, a health analytics company that he founded in 1996. He has more than 30 years of experience in the fields of outcomes research, epidemiology, and informatic...s. Dr. Menzin spearheaded the development and launch of Panalgo’s flagship analytics software, Instant Health Data (IHD). He has authored several dozen papers in medical, pharmacy, and outcomes research journals across a wide range of subjects from clinical trials to program evaluation. He serves as a reviewer for numerous journals, and is a member of many professional associations. Dr. Menzin has a Bachelor’s degree in Economics from the University of Rochester and earned his doctorate in Economics from Boston University. Read more
Jordan Mezin

Jordan Menzin

Chief Technology Officer
Jordan Menzin serves as Chief Technology Officer for Panalgo, where he leads the company's technology strategy and product development. As a technologist and entrepreneur, Jordan created Panalgo's ana...lytics platform, Instant Health Data (IHD), which is now used by leading healthcare companies around the world. Jordan has combined his knowledge of healthcare and technology to help customers turn data into insights, enabling more impactful decisions. He holds a bachelor's degree in Economics from McGill University.  Read more
Catherine Richards

Catherine Richards, PhD, MPH

VP of Analytics & Scientific Engagement
Catherine is the VP of Analytics & Scientific Engagement at Panalgo, where she oversees training and support of the Instant Health Data (IHD) platform as well as the scientific engagement of existing ...customers. Catherine brings a wealth of scientific expertise from over ten years of experience working and teaching in academia, namely at Columbia University in New York. Her advanced degrees in Epidemiology guide her work at Panalgo, reinforcing the science behind the analytical engine. Catherine holds an undergraduate degree from University of Pennsylvania, and an MPH and Ph.D. in Epidemiology from Columbia.  Read more
Mathew Sussman

Matthew Sussman, MA

VP of Modeling & Strategy
Matthew Sussman, MA is VP of Modeling & Strategy at Panalgo. Matt has over 20 years of business-to-business consulting experience, including more than 13 years of experience in health economics and ou...tcomes research. He has published a wide array of outcomes research studies (e.g., health economic models, burden-of-illness analyses, retrospective database analyses, systematic literature reviews) and has provided manufacturers with forward-thinking, strategic insights into the value of treatment interventions across therapeutic and disease areas. Matt has a deep knowledge of ICER’s value assessment framework, best practices, and evaluations, and has led numerous strategic initiatives revolved around ICER assessments. He is a member of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) and is an executive committee member of the ISPOR Boston chapter. Matt received his undergraduate degree in Business Administration from the University of Michigan Ross School of Business and a graduate degree in Economics from Boston University. Read more

Mark Friedman, MD

VP of Medical Affairs
Mark Friedman is VP of Medical Affairs for Panalgo. He is an internist with over 20 years of clinical and pharmacoeconomics consulting experience. He has management experience in the formulary and ma...naged care implementation processes and also plays a major role in the design and implementation of clinically-oriented outcomes research studies, including evidence-based medicine studies, clinical-trial–based evaluations, prospective outcomes studies, and economic models. He is a member of the American Board of Internal Medicine and the American College of Physicians. Dr. Friedman is a graduate of Columbia University and attended the Harvard School of Public Health. Read more
Patty Kellikerv

Patty Kellicker

VP of Marketing
Patty leads marketing at Panalgo, where she spearheads marketing and communication initiatives to support business development efforts, creates and executes product marketing strategy, drives lead gen...eration and manages a team of both in-house and external marketing professionals. Previously, Patty led corporate marketing for GNS Healthcare, an artificial intelligence software company and Humedica, a high growth population health and analytics start-up that was acquired by Optum. She also built and grew her own marketing firm and worked in operations and business development for a national occupational health company where she rolled out the first pharmacy-based flu program for consumers. Patty holds a bachelor’s degree from Georgetown University and is certified in inbound, email marketing, social media and content marketing from HubSpot. Read more

Paul Smith, MBA

VP of Finance
As VP of Finance, Paul runs finance and legal at Panalgo having joined in early 2020. After spending 8 years at the start of his career in the Boston office of Ernst & Young in the assurance practice..., Paul has headed up finance at a number of successful venture and private equity backed companies in the SaaS, Software, Professional Services and Life Sciences industries. He is a Certified Public Accountant in the Commonwealth of Massachusetts and holds an MBA from Northeastern University.  Read more
Tracey Willey

Tracey Willey

VP of Human Resources
Tracey leads all things people and culture at Panalgo. As the company continues to grow, she has led the integration of new systems and processes and has filled key roles within the company. Tracey st...arted her career in finance and business operations leadership roles. Prior to joining Panalgo in 2013, she had 14 years of experience managing human resources and business operations for global consulting firms Aon Management Consulting and Rath & Strong Management Consultants.  Tracey holds a bachelor’s degree from Gordon College. Read more

Strategic Advisory Board

Samy Suissa, PhD

Director of the Centre for Clinical Epidemiology (Lady Davis Institute of the Jewish General Hospital) | Distinguished James McGill Professor (McGill University)
Samy Suissa, PhD, is Director of the Centre for Clinical Epidemiology, Lady Davis Institute of the Jewish General Hospital, and a Distinguished James McGill Professor of Epidemiology and Biostatistics..., and Medicine, at McGill University, Montreal, Canada. He heads the Canadian Network for Observational Drug Effect Studies (CNODES). Professor Suissa has conducted several studies on the real world effects of medications used for different chronic diseases, including respiratory, cardiovascular, diabetes, rheumatoid arthritis, cancer and women’s health. He specializes in research methods and authored over 500 peer-reviewed papers. He has served on the editorial boards of various scientific journals, including Pharmacoepidemiology and Drug Safety, the European Respiratory Journal, Chest, Lancet Respiratory Medicine, Multidisciplinary Respiratory Medicine, and the Journal of COPD. He is a fellow of the Royal Society of Canada and of the Canadian Academy of Health Science, has received the Distinguished Investigator award from the Canadian Institute of Health Research and the FC Donders Professorship Award from Universiteit Utrecht, Netherlands. Read more

Peter J. Neumann, ScD

Director of the Center for the Evaluation of Value and Risk in Health (Institute for Clinical Research and Health Policy Studies, Tufts Medical Center), Professor of Medicine (Tufts University School of Medicine)
Peter J. Neumann, ScD, is Director of the Center for the Evaluation of Value and Risk in Health (CEVR) at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and Pro...fessor of Medicine at Tufts University School of Medicine. He is the founder and director of the Cost-Effectiveness Registry, a comprehensive database of cost-effectiveness analyses in health care. Dr. Neumann has written widely on the role of clinical and economic evidence in pharmaceutical decision making and on regulatory and reimbursement issues in health care. He served as co-chair of the 2nd Panel on Cost-Effectiveness in Health and Medicine. He is the author or co-author of over 250 papers in the medical literature, the author of Using Cost-Effectiveness Analysis to Improve Health Care (Oxford University Press, 2005) and co-editor of Cost-Effectiveness in Health and Medicine, 2nd Edition (Oxford University Press, 2016). Dr. Neumann has served as President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). He is a member of the editorial advisory board of Health Affairs and the health policy advisory boards for the Congressional Budget Office. He has also held several policy positions in Washington, including Special Assistant to the Administrator at the Health Care Financing Administration. He received his doctorate in health policy and management from Harvard University. Read more

Board of Directors

Jeffrey Crisan

Managing Partner (Silversmith Capital Partners)
Jeff co-founded Silversmith Capital Partners in 2015. At Silversmith, Jeff focuses on investments across the firm’s two core verticals, SaaS & Information Services and Healthcare IT & Services. He... currently serves on the Board of Directors of Panalgo, Iodine Software, LifeStance Health, MediQuant, Nordic Consulting, Partners Surgical, and Upperline Health. In addition, he is a Board Observer at Sound Physicians. Jeff spent 14 years as a growth equity investor prior to co-founding Silversmith Capital Partners. Jeff joined Bain Capital Ventures in 2002, where he served as Managing Director from 2009-2014. While at Bain Capital Ventures, Jeff focused predominantly on growth equity investments in the healthcare and technology sectors, with a particular emphasis on healthcare IT, healthcare services, and technology-enabled business services. Prior to Bain Capital Ventures, Jeff worked in Bain Capital’s Private Equity group from 1998-2000, where he focused on technology and healthcare investments. From 1995-1998, Jeff was a consultant at Bain & Company. Some of Jeff’s past investment experience includes ABILITY Network (acquired by Inovalon), Accelecare (acquired by Healogics), Boston Heart Diagnostics (acquired by Eurofins Scientific), Enclarity (acquired by LexisNexis), Liberty Dialysis (acquired by Fresenius Medical Care), MedeAnalytics (acquired by Thoma Bravo), MedHOK (acquired by Hearst), and National Cardiovascular Partners (acquired by Fresenius Medical Care). He received an AB, magna cum laude, in Government and Mathematics from Dartmouth College and an MBA with Distinction from Harvard Business School. Jeff lives with his wife and two children in Belmont, MA. Jeff loves playing most sports, particularly with his kids, and is an avid cyclist. Jeff annually rides the Pan-Mass Challenge, a 192 mile bike ride across Massachusetts, to help raise funds for the Dana-Farber Cancer Institute.  Read more

Jared Kesselheim

Co-founder & Managing Partner (Transformation Capital)
Jared Kesselheim, M.D., brings to Transformation Capital more than fifteen years of investing and clinical experience and has a demonstrated history of identifying compelling companies and helping the...m realize continued innovation, growth and strong exits. Jared co-founded Transformation Capital’s predecessor management company in 2016 and serves on the boards of six Fund I portfolio companies: Vera Whole Health, Scientist.com, Aktana, Protenus, Groups, and Panalgo. Previously, Jared was at Bain Capital Ventures, where he was a leader of their digital health practice, focusing on investments in digital health as part of an $850 million multi-sector fund. He became a Partner of Bain Capital Ventures in January 2014, having previously served as an Associate and Principal after joining that firm in July 2008. During his time at Bain Capital Ventures, Jared was involved in multiple high growth investments including: Apixio (Board Director), Remedy Partners (Board Observer; acquired by New Mountain Capital in 2019), ABILITY Network (Board Director after being Board Observer; acquired by Summit Partners in 2014 and acquired by Inovalon in 2018), MedHOK (Board Observer; acquired by Hearst in 2016), National Cardiovascular Partners (Board Observer; acquired by Fresenius in 2014), and Liazon (Board Observer, acquired by Towers Watson in 2014). Prior to his investing career, Jared completed a residency in Internal Medicine at Massachusetts General Hospital. As a resident physician, he oversaw a primary care panel of 300 patients and directed care teams within the hospital’s general medical wards and the medical intensive care unit. Jared graduated from Harvard College summa cum laude and Phi Beta Kappa with a degree in Biochemical Sciences, where he also co-wrote the 1997 Hasty Pudding Theatricals musical “Me and My Galaxy." He also received an MD from Harvard Medical School and an MBA from Harvard Business School where he was a Baker Scholar and an enthusiastic bench warmer for the HBS Club Hockey team. At home in Newton, Massachusetts, Jared and his wife Dara continue to work in vain on developing strategies for preventing their three young boys from treating all furniture as a form of playground equipment. Read more

Interested in joining our team?